Artificial Intelligence | Machine Learning Wugen | Cellular Therapies for Cancer


Enterprise, Biotechnology, Drug Discovery, Therapeutic, Cell Therapy, Cancer Treatment, Hematology St. Louis, MO , United States

Wugen

Artificial Intelligence | Machine Learning


Wugen | Cellular Therapies for Cancer

Wugen

Biotechnology, Drug Discovery, Therapeutic, Cell Therapy, Cancer Treatment, Hematology


St. Louis, MO , United States

Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies. Our lead program, WU-NK-101 is being tested in Phase 1b clinical trials. As the first product derived from our memory NK cell therapy platform, WU-NK-101 has shown robust efficacy (and safety) in AML patients.

The company is engaged in developing a pipeline of off-the-shelf memory natural killer (NK) cell therapies to treat a broad range of hematological and solid tumor malignancies, enabling the medical community to effectively combat life-threatening tumors.

 

B2B

51 to 100

Series B

$172 M

Scaling Up

2018

 
 

Biotechnology

N/A

N/A

 
 

Service

Yes

Active

 
 

   Machine Learning


Drug Discovery

Drug Discovery


N/A

 

   Software


N/A


Machine Learning Algorithm

Machine Learning Algorithm

 
 

Jul 2021

  • Wugen Raised $172M in Series B Funding

Apr 2021

  • Wugen Hired Daniel Kemp, Ph.D., as Chief Executive Officer

Mar 2021

  • Wugen Partnered with Alpha Biopharma in Asia

Mar 2021

  • Wugen Announced Exclusive License Agreement With HCW Biologics
 
 

View All

Chief Financial Officer

St Louis, MO

Head of NK Process Development

St Louis, MO

Scientist / Engineer: CMC Technology Transfer

St Louis, MO

Associate Director/Director, Clinical Quality Assurance

San Diego, CA

 

AI/ML Professionals

Want to work at Wugen?

We can introduce you to the right person at Wugen

Talk to our Talent Team

 

9

1

$172M

Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round

 
 

Date

Round

$ Raised

Investors

07/15/2021

Series B

$172M

Tybourne Capital Management, Sands Capital, RiverVest, LYZZ Capital, Lightchain Capital, Intermediate Capital Group, Fidelity, Falcon Edge Capital, Aisling Capital, Abingworth

Date : 07/15/2021

Round: Series B

$ Raised: $172M

Investors: Tybourne Capital Management, Sands Capital, RiverVest, LYZZ Capital, Lightchain Capital, Intermediate Capital Group, Fidelity, Falcon Edge Capital, Aisling Capital, Abingworth

 

Investors

Interested in researching Wugen?

We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Wugen

Request a Demo - Deal Souring Platform

 
 Dan Kemp


Dan Kemp
Chief Executive Officer

Ayman Kabakibi


Ayman Kabakibi
Chief Operating Officer, Executive Vice President of Research & Development

 Mark Lewis


Mark Lewis
Vice President, Finance and Business

Tara Heskett


Tara Heskett
Head Of Human Resources

 Sandra Teixeira


Sandra Teixeira
EVP, Head of Strategy and Development Operations

 
 

Potential Customers

Interested in what they do or partnership?

Learn more about how they work

Schedule a Call w/ Wugen